The Impact of COVID-19 on the Pharmaceutical Market

JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. Long discusses the data trends for pharmaceutical companies during COVID-19 and, most importantly, how these trends impact healthcare patients.

Prescription Stockpiling: With news of the impending pandemic, patients around the US began to stockpile 90-day prescriptions in March. As a consequence, the pharmaceutical marketplace experienced a major decrease in demand in the following two months. Long describes the effects of this “prescription rush” and subsequent demand decrease on the pharmaceutical industry.

Access Prescriptions and Shortages: JC and Long discuss methods by which patients are receiving their prescriptions during COVID-19. Mail-order and other socially distant methods (such as deliveries) have grown in popularity. Long also details how the pharmaceutical industry has responded to recent supply chain shortages. Overall, he is impressed by the resilience of the pharmaceutical supply chain (which includes manufacturing, PBMs, pharmacies, wholesalers, and logistics companies) during COVID-19.

Growth of TeleHealth: Long touches on the impact of telehealth on the healthcare marketplace and medical prescriptions. He notes the dramatic growth of telehealth in a matter of just a few months, and he believes that telehealth is here to stay. However, he cautions that telehealth may have a negative impact on prescription trends for patients.

You can subscribe to The Pharmacy Benefit on Spotify, Google Podcasts, Apple Podcasts, and all other major platforms.